Literature DB >> 1678202

Positive signal transduction via surface CD4 molecules does not need coexpression of the CD3/TcR complex.

S Carrel1, S Salvi, P Gallay, C Rapin, R P Sekaly.   

Abstract

We previously reported that the human CD4 molecule is capable of transducing a positive signal when activated by an anti-CD4 mAb B66. This antibody, in contrast to many other anti-CD4 mAb, induced IL2 production and proliferation of resting CD4+ peripheral blood T lymphocytes in the absence of any other signal. We further reported that anti-CD4 mAb B66 was able to induce IL2 production in murine T-cell hybridoma cells transfected with full-length human CD4 cDNA. In the present study, we extend these findings by demonstrating that anti-CD4 mAb B66 was able to induce Ca2+ mobilization and IL2 production in a CD3/TcR- variant 31-13, of the CD3/TcR+ Jurkat cell line. We further showed that anti-CD4 mAb B66 was able to activate CD4+ cells from the promonocytic cell line U937. In these cells, mAb B66 induced Ca2+ mobilization when cross-linked with a second antibody and, in addition, the production of large quantities of IL1 beta was measured. In essence, our findings provide direct evidence that cross-linking of CD4 may cause T-cell activation in the absence of the coexpression of the CD3/TcR molecular complex and that, in addition, CD4 might transduce a positive signal in CD4+ cells of the myeloid lineage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678202     DOI: 10.1016/0923-2494(91)90017-d

Source DB:  PubMed          Journal:  Res Immunol        ISSN: 0923-2494


  2 in total

1.  Expression and release of interleukin-1 by human glioblastoma cells in vitro and in vivo.

Authors:  T Gauthier; M F Hamou; L Monod; P Gallay; S Carrel; N de Tribolet
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

2.  Boosting regulatory T cell function by CD4 stimulation enters the clinic.

Authors:  Christian Becker; Tobias Bopp; Helmut Jonuleit
Journal:  Front Immunol       Date:  2012-06-18       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.